Lakefront Biotherapeutics NV (LKFT) — Cash Flow Quality Index
Lakefront Biotherapeutics NV (LKFT) has a Cash Flow Quality Index of -16.17x as of June 2026. Operating cash flow of $-34.09 Million is below net income of $2.11 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Lakefront Biotherapeutics NV debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Lakefront Biotherapeutics NV Cash Flow Quality Index (2023–2025)
Historical Cash Flow Quality Index for Lakefront Biotherapeutics NV across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. See Lakefront Biotherapeutics NV (LKFT) net asset quality to measure how much of total assets are equity-financed.
Annual Cash Flow Quality Index for Lakefront Biotherapeutics NV (2023–2025)
Year-by-year earnings quality comparison for Lakefront Biotherapeutics NV. For the full cash flow conversion analysis, see LKFT operating cash flow.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.80x | $-257.46 Million | $320.88 Million | ▲ +81.4% |
| 2024 | -4.32x | $-320.03 Million | $74.08 Million | ▼ -125.3% |
| 2023 | -1.92x | $-405.97 Million | $211.70 Million | — |